<SEC-DOCUMENT>0001209191-23-004584.txt : 20230124
<SEC-HEADER>0001209191-23-004584.hdr.sgml : 20230124
<ACCEPTANCE-DATETIME>20230124161050
ACCESSION NUMBER:		0001209191-23-004584
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230120
FILED AS OF DATE:		20230124
DATE AS OF CHANGE:		20230124

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Klencke Barbara
		CENTRAL INDEX KEY:			0001647647

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39866
		FILM NUMBER:		23548254

	MAIL ADDRESS:	
		STREET 1:		C/O SIERRA ONCOLOGY, INC.
		STREET 2:		1820 GATEWAY DRIVE, SUITE 110
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94404

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			eFFECTOR Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001828522
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				853306396
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		142 NORTH CEDROS AVENUE, SUITE B
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075
		BUSINESS PHONE:		(858) 925-8215

	MAIL ADDRESS:	
		STREET 1:		142 NORTH CEDROS AVENUE, SUITE B
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Locust Walk Acquisition Corp.
		DATE OF NAME CHANGE:	20201015
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-01-20</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001828522</issuerCik>
        <issuerName>eFFECTOR Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>EFTR</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001647647</rptOwnerCik>
            <rptOwnerName>Klencke Barbara</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O EFFECTOR THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>142 NORTH CEDROS AVENUE, SUITE B</rptOwnerStreet2>
            <rptOwnerCity>SOLANA BEACH</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92075</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.4688</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-01-20</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>28125</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-01-19</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>28125</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>28125</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on January 20, 2023, subject to the Reporting Person's continued service with the Issuer through each vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Michael Byrnes, Attorney-in-Fact for Barbara Klencke</signatureName>
        <signatureDate>2023-01-24</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
